Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02803203
Title Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Bevacizumab + Osimertinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.